TD Private Client Wealth LLC Has $1.14 Million Stake in Baxter International Inc. (NYSE:BAX)

TD Private Client Wealth LLC decreased its stake in shares of Baxter International Inc. (NYSE:BAX) by 4.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,045 shares of the medical instruments supplier’s stock after selling 1,982 shares during the period. TD Private Client Wealth LLC’s holdings in Baxter International were worth $1,139,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Riverview Trust Co increased its stake in shares of Baxter International by 5,488.2% during the fourth quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 933 shares during the period. LRI Investments LLC grew its holdings in Baxter International by 60.8% in the 3rd quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 590 shares in the last quarter. CKW Financial Group increased its position in Baxter International by 100.0% during the 3rd quarter. CKW Financial Group now owns 2,200 shares of the medical instruments supplier’s stock worth $81,000 after buying an additional 1,100 shares during the period. Bruce G. Allen Investments LLC lifted its holdings in shares of Baxter International by 247.3% during the fourth quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier’s stock worth $76,000 after buying an additional 1,867 shares in the last quarter. Finally, West Oak Capital LLC boosted its position in shares of Baxter International by 345.3% in the fourth quarter. West Oak Capital LLC now owns 3,785 shares of the medical instruments supplier’s stock valued at $110,000 after acquiring an additional 2,935 shares during the period. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Price Performance

Shares of BAX stock opened at $33.22 on Monday. The business has a fifty day simple moving average of $32.91 and a 200 day simple moving average of $33.81. The company has a market cap of $16.99 billion, a P/E ratio of -25.95, a P/E/G ratio of 0.93 and a beta of 0.60. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31. Baxter International Inc. has a twelve month low of $28.34 and a twelve month high of $43.99.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.52 by $0.06. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. The business had revenue of $2.75 billion during the quarter, compared to analysts’ expectations of $2.67 billion. On average, sell-side analysts forecast that Baxter International Inc. will post 2.48 EPS for the current fiscal year.

Baxter International Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.68 dividend on an annualized basis and a yield of 2.05%. Baxter International’s dividend payout ratio is currently -53.13%.

Analysts Set New Price Targets

A number of research firms recently commented on BAX. Citigroup lowered their price target on shares of Baxter International from $37.00 to $35.00 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. Argus raised shares of Baxter International from a “hold” rating to a “buy” rating in a report on Monday, February 24th. The Goldman Sachs Group assumed coverage on Baxter International in a research note on Wednesday, February 26th. They issued a “buy” rating and a $42.00 price target for the company. JPMorgan Chase & Co. lowered their price objective on Baxter International from $38.00 to $36.00 and set a “neutral” rating on the stock in a research note on Friday, February 21st. Finally, Barclays upped their target price on Baxter International from $39.00 to $41.00 and gave the company an “overweight” rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Baxter International presently has an average rating of “Hold” and an average target price of $38.56.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.